Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PharmaMar
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women aged 18 years or older.
Presence of platinum-sensitive relapsed ovarian cancer.
Treatment and treated indication according to local label SmPC and reimbursement for trabectedin and PLD treatment.
Prior treatment with a minimum of 1 cycle of trabectedin + PLD according to SmPC before inclusion in the study, and no more than 3 previous treatment lines.
Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.
You may not be if
None
Clareo Health | Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
